

Halitosis: a new definition and classification

This is proof print, not original paper. Purchase original paper online at:

<http://www.nature.com/bdj/journal/v217/n1/abs/sj.bdj.2014.552.html>

Cited as:

Aydin M. , Harvey-Woodworth CN. Halitosis: a new definition and classification. British Dental Journal, 2014; 217: E1 doi 10.1038/sj.bdj.2014.552

About authors

Author: Murat Aydin.

Academic affiliate: DDS, PhD. Dental Professional, Doctor of Philosophy on Microbiology

Work affiliations: Private Clinical Practice.

Address: Office:Adana-Turkiye

Home: Adana-Turkiye

Email: aydinmur@gmail.com, aydinmur@yahoo.com, m-aydin@doctor.com

Web: <http://www.aydinmur.com>



Author: Harvey-Woodworth CN, BDS MFDS(i)

Academic affiliate: N/A

Work affiliations: Private practise, UK

Address: Office: (Not corresponding author)

Home: (Not corresponding author)

Tel:

Cell phone:

Email: (Not corresponding author) harvey.mmx@gmail.com

Web: N/A

Halitosis: a new definition and classification

ABSTRACT

There is no universally accepted, precise definition, nor standardization in terminology and classification of halitosis. This paper reviews the previous approaches and highlights inconsistencies and redundancies.

A new definition, free from subjective descriptions (fecal, fish odor, etc.), one time sulfide detector readings and organoleptic estimation of odor levels, and excludes temporary exogenous odors (e.g. from dietary sources). Some terms previously used in the literature are revised.

A new etiologic classification is also proposed, dividing pathologic halitosis into Type 1 (oral), Type 2 (airway), Type 3 (gastroesophageal), Type 4 (blood-borne) and Type 5 (subjective). In reality, any halitosis complaint is potentially the sum of these types in any combination, superimposed on the Type 0 (physiologic odor) present in health.

This system allows for multiple diagnoses in the same patient, reflecting the multifactorial nature of the complaint. It represents the most accurate model to understand halitosis and forms an efficient and logical basis for clinical management of the complaint.

Aydin M. , Harvey-Woodworth CN. Halitosis: a new definition and classification. British Dental Journal, 2014; 217: E1 doi 10.1038/sj.bdj.2014.552

LITERATURE REVIEW

Previous definitions

Halitosis is receiving increasing scientific interest, but still no accepted definition exists. In the literature, definitions include: "the subjective perception after smelling someone's breath, if unpleasant",^[1] "noticeably unpleasant odors exhaled in breathing",^[2] "an oral health condition characterized by unpleasant odors emanating consistently from oral cavity",^[3] "general term to describe any disagreeable odor of breath, regardless of its origin",^[4] and "an unpleasant odor emanating from oral cavity."^[5]

Many definitions are inadequate, ignoring the potential emanation of odors via the mouth and nose from the respiratory and gastroesophageal tracts, transfer of volatiles from blood to breath during alveolar gas exchange, and also self-perception of halitosis by the patient. To varying degrees, the breath

always has odorant volatiles, originating orally or elsewhere. None set a clear boundary between normal, physiologic breath odor and, pathologic halitosis. Negative identification of an odor requires qualification. Who determines this? The patient, the patient's social environment, or the clinician by sulfide detectors (halitometers)? Some refer to exogenous odorants (e.g. garlic) as halitosis, yet this is not pathologic. To distinguish normality from disease, a more precise definition and classification is needed.

This paper reviews previous attempts at classification and definition of halitosis, and forwards a new scheme. The diagnosis and treatment of halitosis according to this scheme are discussed in a separate publication.




Fig.1 Two previous classifications. Miyazaki *et al.* 1999 is generally the most widely used, but neither is universally accepted.^[5]

Previous classifications

Miyazaki *et al.* 1999 suggest genuine halitosis, pseudo-halitosis and halitophobia (Fig 1).^[6] Genuine halitosis is divided into physiological or pathological, then the latter is split into oral and extra-oral. This was adapted to North American society with regards halitophobia, and appeared in publications a decade ago.^[7-9] This classification is inflexible since multiple diagnoses for one patient are not enabled. The broad category "extra-oral, pathologic halitosis" does not aid referral choice, or help the receiving clinician, and is also poor for researchers who need to precisely classify extra-oral halitosis according to etiology. "Morning breath" is not placed in the oral category, despite manifesting orally. Inappropriately, two out of three categories (pseudo-halitosis and halitophobia) have psychopathologic connotations, and, they are excluded from pathologic halitosis. Subjective halitosis can be caused by psychologic or neurologic factors, which are technically extra-oral

processes, yet "extra-oral halitosis" is again excluded from pathologic halitosis. After treatment, whether for genuine halitosis or pseudo-halitosis, if the patients continue to believe they have halitosis, reclassification to halitophobia occurs. This categorizes cases according to treatment outcome, as halitophobia is diagnosed following a treatment failed. This scheme claims to provide treatment needs, but how can these be determined beforehand if they depend on results of treatment? Pseudo-halitosis is misleading when considered alongside other medical terms, e.g. pseudo-Cushing's syndrome, intestinal pseudo-obstruction, pseudo-lymphoma or pseudo-Kaposi's sarcoma. These exist as physical entities which masquerade as their namesake. Pseudo-halitosis implies a genuine, physical condition mistaken for halitosis non-existent. Similarly, halitophobia suggests an irrational fear, but instead refers to where the patients believe their treatment unsuccessful.

Tangerman and Winkel suggest intra- and extra-oral halitosis, the latter then divided into non-blood-borne and blood-borne.^[10] An earlier publication divides extra-oral halitosis into blood-borne, upper respiratory tract and lower respiratory tract.^[11] They list 4 etiologic mechanisms of blood-borne halitosis: systemic diseases, metabolic disorders, food and medications.^[10] These authors use “pseudo-halitosis/halitophobia” to describe non-measurable halitosis, whilst retaining their own classification for measurable halitosis.^[12] In reality, this classification focuses on oral and blood-borne halitosis, with insufficient categorization of physiologic, sinonasal, laryngopharyngeal, gastroesophageal, or psychologic causes. The significance of blood-borne halitosis relative to other extra-oral mechanisms is unclear, and a broad division into blood-borne and non blood-borne may be inappropriate. Again, this system does not allow for multiple diagnoses, making accurate categorization of some cases difficult, and there is no distinction between pathologic and physiologic halitosis.

Motta *et al.* suggest primary halitosis (“respiration exhaled by the lungs”), and secondary halitosis (“originates in mouth or upper airways”).^[13] It is unclear if primary halitosis refers to blood-borne halitosis, odor from the lower respiratory tract itself, or both. This is seldom used, perhaps because the clinical utility is limited by not addressing subjective halitosis or gastroesophageal halitosis.

Previous terminology

In some cases, odor is not detected organoleptically and volatile sulfur compound (VSC) levels are normal. There is no local or systemic condition, and no reliable, third party

confidants confirming the complaint. This scenario is generally ascribed to psychologic factors, termed imaginary halitosis,^[14] delusional halitosis,^[15] pseudo-halitosis,^[7] non-genuine halitosis,^[16,17] chronic olfactory paranoid syndrome,^[18] anthropophobia (taijin kyofusho),^[19] halitophobia,^[20] olfactory reference syndrome (ORS),^[21,22] and social anxiety disorder.^[23] These terms may easily cause confusion.

The term psychosomatic halitosis is incorrectly used when referring to subjective halitosis complaints. Psychosomatic disorders are disorders in which psychologic factors play a significant role, and there are physical symptoms which are detectable clinically. However, the term psychosomatic halitosis is used to describe an odor that is clinically nonexistent.

Terms which refer to odor character promote confusion for clinicians and patients e.g., sulfurous/fecal, fruity, and ammoniacal/urine-like; respectively attributed to VSC, acetone, and ammonia with other amines.^[10] Sweet, musty or fishy are used to describe particular halitosis types. However, fish odor is nonspecific for trimethylaminuria (TMAU),^[24] as is acetone for diabetes. All individuals have detectable breath acetone >400 ppb,^[25,26] especially when fasting. Fish odor can be perceived as musty, and acetone as sweet. The sweet, musty aroma in liver failure has been termed fetor hepaticus.^[27] This is also described as fecal, “the smell of dead mice” or “the breath of the dead”.^[28]

Other terms include “denture odor”,^[29] “uremic fetor” in renal failure,^[30] and “rotten egg” in poor oral hygiene. All these terms are subjective and open to misinterpretation. There is no standardization in terminology, which has led to discrepancies developing

where some authors use a term with one definition and others with different meaning.

- Oral malodor, oral halitosis, tongue malodor, odontogenic halitosis, pathological halitosis, objective halitosis, genuine halitosis and intra-oral halitosis are used incorrectly as synonyms for halitosis.^[31] E.g. oral malodor includes all odors originating orally, not just the tongue; but not all pathologic/objective halitosis originates orally.
- Pseudo-halitosis, psychosomatic halitosis, halitophobia or self- and imaginary halitosis are also sometimes used interchangeably,^[32] as with non-genuine, delusional and phantom halitosis, but they not synonymous, e.g., halitophobia describes a fear; self-halitosis describes clinically existent, self-producing odor; imaginary halitosis describes halitosis produced psychologically; and phantom halitosis is neurologic.
- Morning breath is sometimes used instead of physiologic halitosis, but these are also dissimilar. Not all 'morning breath' is physiologic.

NEW DEFINITION OF HALITOSIS

Objective halitosis has been defined as "malodor with intensity beyond a socially acceptable level perceived".^[7] This is independent from halitometric readings and subjective odor descriptions. This should be a basic definition of objective halitosis, but must be qualified with several important points:

- A halitosis complaint may be **objective**, where there is an unpleasant

odor endogenously produced anywhere in the body, emitted from the mouth and/or nose and detectable to others; or **subjective**, where there is no detectable odor to others but the patient complains of its presence.

- Anyone who complains of halitosis, objective or subjective, should be considered a "halitosis patient".
- Evidence of objective halitosis is a clinical picture built of (i) reliable reports from the patient's social environment e.g. family members or close friends, (ii) patient's self declaration of halitosis, and to a lesser extent (iii) halitometric readings.
- A lack of complaints from the patient's social environment including family members, suggests that there is no objective halitosis. Furthermore, if there are no complaints from either the patient or his/her social environment, this usually implies that there is no need to diagnose halitosis or treat, even if halitometric measurements appear to indicate the presence of elevated VSC. As a rule, halitometers measure VSC, not halitosis.
- Halitosis is considered unpleasant by the patient and his/her social environment. If the odor is not perceived negatively, it is not halitosis.
- Halitosis is almost always chronic in nature, although it may be intermittent.
- Some diseases (tonsillitis, pharyngitis, etc.) or transient oral flora or metabolic changes in the body may cause bad odor in the short term (< 2 months), which disappears when the condition resolves. Such bad odors are called temporary halitosis.
- Some volatile foodstuffs possess specific odors (e.g. garlic, onion) and

may cause short term halitosis (“dietary odor”), as with certain medications or intoxications. All are called temporary halitosis, managed with reassurance and advice, and further diagnosis or treatment is unnecessary.

NEW CLASSIFICATION OF HALITOSIS

Types 1 - 5 (Fig. 2) represent different odor mechanisms, which may be present in any combination at any time. Potentially, each type of pathologic halitosis (Type 1 - 5) is superimposed on physiologic odor (Type 0). At any given time, pathologic halitosis is the sum of the all these types sources, as well as

their respective underlying physiologic contributions.

The relative contributions of these different physiologic and pathologic etiologies is subject to interpersonal variation, and may fluctuate even within hours in the same individual. Sometimes the level of one or more types may be so low as to give negligible contributions to the overall complaint, or there may be multiple contributing factors in the same patient. This can be recorded as Type 1+3, Type 2+4, Type 1+4+5 halitosis, etc. Previous classifications oversimplify halitosis, and this new classification is the most representative model proposed.




Fig.2 New etiologic classification is proposed.

Physiologic (Type 0) halitosis consists of the sum of the physiologic aspects of oral (Type 1), airway (Type 2), gastroesophageal (Type 3), and blood-borne (Type 4) subjective (Type 5) odors at any particular time, potentially superimposed on halitosis concern.

Type 0 halitosis: *Physiologic halitosis*

Type 0 halitosis represents the sum of the physiologic contributions of oral, airway, gastroesophageal, blood-borne and subjective halitosis that are potentially present in every healthy person, in any combination. All healthy individuals have a certain level of bacterial activity in the mouth and on respiratory tract mucosae. In addition there is a potentially a negligible amount of gas leakage from the gastroesophageal tract, and blood gases are transferred to the exhaled breath during gas exchange in pulmonary alveoli. Therefore, minimal amounts of types 1 - 5 potentially exist in health. The total level of odor, and the relative contributions of these different sources of physiologic odor, is subject to both interpersonal variation, and also variation in the same individual from one occasion to the next.

Table.1 Physiologic halitosis should not be confused with a low level of oral (type 1) halitosis since there are differences

	Type 0	Type 1
Duration	Always present; fluctuating	While a cause exists
Originates	Mouth + elsewhere	Mouth only
Detectable on	Mouth air + breath	Mouth air
Offensive?	Possibly	Yes
Treatable?	No	Yes
Preventable?	No	Yes
Detectable by halitometer?	Yes	Yes

One or multiple types may exist in any combination at any time, varying according to

many different factors, including hydration, oral hygiene, microbiota, salivary flow rate, nature of last food consumption, biochemical, hormonal, mechanic activity of the body, fasting, sleep, digestive enzyme profile in gut, momentarily amino acid and electrolyte profile in serum etc. It is distinguished from oral halitosis (See Table 1).

Type 1 halitosis: *Oral halitosis*

The gases that contribute to Type 1 (oral) halitosis are (greatest to least): VSC, volatile organic compounds (VOC) and nitrogen containing gases (amines).^[33] The main VSC involved are hydrogen sulphide (H₂S), methyl sulfide (CH₃SH, or methyl mercaptan, MM), and dimethyl sulfide ((CH₃)₂S, DMS). Nearly 700 different compounds have been detected orally,^[35] including indole, skatole, acetic acid and short chain acids (e.g. butyric, valeric, isovaleric, lactic, caproic, propionic and succinic acids). In halitosis patients, the 30 most abundant VOC in mouth air are alkanes or alkane derivatives, and of these the most common are methyl benzene, tetramethyl butane, and ethanol.^[34] Alkanes are aromatic breakdown products from reactive oxygen species acting on inflamed tissues.^[34] Others report acetone, methenamine, isoprene, phenol, and D-limonene are the most abundant organic compounds in mouth air in oral halitosis patients. The organoleptic level of oral halitosis correlates with VSC,^[35] and amines (such as putrescine, cadaverine, and trimethylamine).^[36]

The gases responsible for oral halitosis are byproducts of protein and glycoprotein putrefaction by the oral microbiota. The dorso-posterior tongue is the most important halitogenic site, by virtue of having both the largest surface area and the highest bacterial

load, within a densely populated biofilm.^[37-39] The most common factors include poor oral hygiene, plaque stagnation areas, gingivitis, tongue coating; and account for ~85% cases.^[31] However, a degree of oral bacterial action is continuously present in health, even with impeccable oral hygiene, and this constitutes the physiologic part of Type 1 halitosis.

Specific bacteria, especially anaerobes, are suggested to cause oral halitosis.^[40,41] In reality, most oral bacteria are potentially odorigenic, releasing VSC, VOC and/or amines. Depending upon the constituents of the gas produced by oral bacteria and ecologic factors in the mouth (e.g. microbiota compositional fluctuations, available nutritional substrate, bacterial metabolism) momentarily determine the composition and level of odor. Therefore, the diagnostic value of the odor character at any one time is questionable. To consider some bacteria as odorigenic and others as non-odorigenic is oversimplification. In reality every bacterium is odorigenic, and there is a continuous spectrum from low to high degree of odor formation capability.^[33,42]

Other possible origins of oral halitosis include: periodontal disease, acute necrotizing ulcerative gingivitis, osteoradionecrosis, large carious cavities, blood/thrombi (e.g. extraction sockets), ulceration, interdental food packing, oral prostheses (dentures, orthodontic appliances, bridges).

Type 2 halitosis: Airway halitosis

Type 2 halitosis originates from the respiratory tract itself (rhinosinusitis, tonsillitis, pharyngitis, laryngitis, bronchitis, pneumonia), anywhere from nose to alveoli. Odorous gases produced by various

respiratory pathoses, held in the exhaled breath and expressed via the nose or mouth. This should be distinguished from type 4 (blood-borne) halitosis, where volatiles from the systemic circulation are transferred during gas exchange to the breath. Some studies report the proportion of halitosis cases that are due to upper respiratory tract pathology to be between 2.9 and 10%.^[31,43-47]

Halitosis is considered a regional symptom of chronic rhinosinusitis, and some report as many as 50-70% will complain of halitosis.^[48,49] In pediatric patients, one of most frequent symptoms is halitosis together with cough, rhinorrhea and sniffing,^[50] even when nasal obstruction, postnasal exudate, pain, sneezing and secretion are clinically absent.^[51] Sinonasal anatomic variations (e.g. agger nasi cells, pneumatization of turbinates or septum; deviated nasal septum) are very commonly found together with mucosal pathoses including rhinosinusitis.^[52]

Post nasal drip is where mucus drains onto the dorsal tongue via the nasopharynx.^[53] This is related to allergic rhinitis, however the existence of post nasal drip as a clinical entity disputed as this occurs in health and there is no agreed definition or pathologic changes.^[54] Mucus stagnation provides a proteinaceous medium for more bacterial putrefaction, but the relationship between halitosis and post nasal drip has not been formally investigated.

Obstructive nasal pathology causes mouthbreathing, possibly resulting in xerostomia and halitosis.^[13,55]

Tonsillitis causes edema and hypertrophy, which may obstruct orifices on tonsillar surface. This disrupts the cleansing flow of secretions, and desquamated epithelial and bacterial cells, extracellular matrix and food debris become trapped, leading to

stagnation. Bacteria putrefy local substrate and release VOC and VSC, expressed on the breath as halitosis with a similar mechanism operates on tongue surface. Crypt debris may mineralize, similar to the transformation of dental plaque to dental calculus. These mineralized deposits are termed tonsilloliths (tonsil stones). The presence of tonsilloliths is strongly associated with abnormal VSC levels.^[46] They are asymptotically present in up to 10% of the general population.^[56] Anaerobic bacteria detected in tonsilloliths include *Eubacterium*, *Fusobacterium*, *Porphyromonas*, *Prevotella*, *Selenomonas* and *Tanarella spp.*, all associated with the production of VSCs.^[57]

Odoriferous gases from the mouth or present in oronasal secretions can excite olfactory receptors and be perceived as halitosis,^[58] even if no halitosis can be detected halitometrically. This is retronasal olfaction and is usually misdiagnosed.

"Airway reflux" describes gaseous or liquid gastric contents refluxing to the pharynx, oral cavity, nasal cavity, paranasal sinuses or even the middle ear,^[59] and is sometimes said to be a cause of halitosis, however there is little credible evidence for this mechanism.

Other respiratory tract causes of halitosis include: laryngitis, tracheitis, bronchitis, bronchiectasis, pneumonia, tuberculosis, nasal foreign bodies, rhinoliths, atrophic rhinitis (ozena), abscesses (peritonsillar, nasopharyngeal, lung), and carcinomas (nasal, sinuses, pharyngeal, lung).^[10,60-65]

Type 3 halitosis: *Gastroesophageal halitosis*

Type 3 halitosis is leakage of odorant volatiles from the stomach via the esophagus to the

mouth and nose. This should be distinguished from volatiles in the GI tract being absorbed into the systemic circulation and exhaled (Type 4, blood-borne halitosis). A degree of gastroesophageal reflux is considered normal, occurring in almost all individuals several times per day.^[66] In a study of 14 healthy individuals, 1.2 ml/10 min gas leakage from the stomach to the esophagus whilst lying horizontal and 6.8 ml/10 min while sitting was demonstrated.^[67] If odorous, this constitutes the physiologic part of gastroesophageal halitosis.

Pathologic level of gastroesophageal halitosis is said to occur due to i) gastroesophageal reflux disease (GERD), ii) *Helicobacter pylori* related gastritis, or iii) other causes e.g. gastrocolic fistulae, Zenker diverticulum and hypopharyngeal diverticulae.^[66] Falcao *et al.* argued that certain GI disorders can cause taste disturbance. Taste receptor cells are associated with lingual papillae, but also present on the palate, epiglottis and upper esophagus. Low intensity acid reflux can cause phantom taste sensations, which may manifest as subjective halitosis.^[16]

Evidence for GERD-related halitosis is contradictory. Some studies report self reported/subjective halitosis complaints are associated with GERD.^[68-71] One study reported gastroesophageal pathology in >50% of patients complaining of halitosis,^[72] whilst others report that GI disorders may account for up to 5% of objective halitosis complaints.^[31] A systematic review investigated the relationship between GERD and halitosis (among other things). Three studies were included, and the authors concluded halitosis is a possible extra-esophageal symptom of GERD,^[73] however 2

of these studies utilized questionnaires (i.e. subjective halitosis). Yoo *et al.* report *H. pylori* infection correlated with elevated VSC in mouth and mucosal erosions,^[74] posing halitosis as a potential biomarker to distinguish between erosive (200 ppb) and (75 ppb) non-erosive GERD.^[75] Gas chromatography on gastric juice and biopsies in these subjects found resolved 7.5 ppm significantly higher H₂S and expression of VSC-releasing enzymatic activity in the erosive group, and 0.5 ppm in the non-erosive group.^[74] However, another study reported no significant difference in halitosis parameters when comparing erosive and nonerosive GERD.^[76] Others have suggested the stomach rarely causes halitosis,^[10] gastroscopy in halitosis patients is entirely unnecessary,^[12] as the findings do not correlate with halitosis.^[77] It has also been argued that there is no evidence that odorous substances are formed in the stomach.^[12] Another study reported no statistically significant difference in the prevalence of halitosis symptoms between children with GERD and those without.^[78]

H. pylori infection also has a controversial role. *H. pylori* possesses a strain-dependent ability to synthesize H₂S and MM from combined cysteine-methionine substrate *in vitro*.^[79] Elevated levels of both hydrogen cyanide and hydrogen nitrate were detected on the breath of *H. pylori* infected patients compared to healthy controls,^[80] however whether this represents type 3 or type 4 (blood-borne) halitosis is unknown.

Oral *H. pylori* colonisation without gastritis may cause Type 1 (oral) halitosis. PCR detected *H. pylori* in 6.4% (21/326) of saliva samples from non-dyspeptic individuals complaining of halitosis. *H. pylori* was associated with higher MM concentration.^[81]

Improvements in halitosis (defined by various methodologies) following eradication therapy are reported.^[82-87] Positive correlation between *H. pylori* and halitosis is reported by some studies,^[88-90] however some of these can be criticized for relying on self reported halitosis rather than semi-objective breath analysis.^[91] Others report no statistically significant correlation.^[69,77,91-93]

This mechanism is rarely responsible for halitosis, but cannot presently be dismissed due to several studies which support the idea that GI disease may cause halitosis.

Type 4 halitosis: Blood-borne halitosis

Type 4 (blood-borne) halitosis is where volatile chemicals in the systemic circulation can transfer to exhaled breath during alveolar gas exchange and cause halitosis.^[94]

Volatiles are endogenously produced, mostly by-products of biochemical metabolic processes.^[11] The concentration of volatiles on the exhaled breath reflects their respective arterial concentrations,^[24] Healthy subjects' breath contains 3481 VOCs,^[95] constituting the physiologic aspect of Type 4 halitosis (Table 2).

Methylated or low carbon containing alkanes, cyclic hydrocarbons, alcohols and aldehydes have an especially pungent odor when they exceed specific odor thresholds for the individual or his/her social environment, constituting pathologic Type 4 halitosis.

Table 2: Example aromatic gases exhaled in healthy individuals

Breath gas	Normal level (ppb)	Ref#	Associated with
Ammonia	833	[25]	Protein or amino acid metabolism, nitrogen metabolism
	422-2390	[96]	
	688	[97]	
Acetone	477	[25]	Lipid metabolism
	661.3	[98]	
	462	[26]	
	293-870	[96]	
Methanol	461	[25]	Abnormal gut flora, renal or pancreatic insufficiency, carbohydrate malabsorption
	32-1684	[99]	
Ethanol	112	[25]	Bacterial overload in gut
	27-153	[96]	
	184 (7-18 age)	[26]	
Isoprene	106	[25]	Cholesterol synthesis
	117.6	[98]	
	212	[100]	
Propanol	18	[25]	Pancreatic insufficiency
	20	[26]	
Acetaldehyde	22	[25]	Alcohol metabolism
	10	[100]	
	24	[101]	
Butane	2.4	[102]	Protein oxidation /colonic bacteria
Alkanes C13-C20	1.5×10^{-10} M/l	[103]	Oxidative stress
Dimethyl Sulfide	0.2 nMol/l	[12, 104]	Hepatic metabolism
Hydrogen*	<10 ppm	[105]	Carbohydrate metabolism in gut

* Hydrogen is odorless, but its elevation >10 ppm in breath may indicate small intestinal bacterial overgrowth syndrome, ileocaecal valve syndrome, ileitis, or carbohydrate malabsorption/intolerance.^[106,107] Along with methane, hydrogen is an indicator gas used in disaccharide malabsorption tests to detect intestinal gases exhaled in breath.^[105] Odorous breath gases (type 4 halitosis) are potentially present when breath hydrogen is elevated.^[33]

The threshold concentration for any given chemical depends on the change in intensity (odor strength) with concentration and the odor character. There is also interpersonal variation in emotional reactions to detected odor; some may react positively and others negatively.^[108] A single volatile chemical can be perceived at lower concentrations than expected when it is combined in a mixture of thousands of VOC like the breath by interaction with other

odorants and collective stimulation of olfactory receptors.

Artificial systems containing chemical sensor arrays for the detection of breath volatiles allow for profile readings of multiple compounds instead of single sensors for a single volatile.^[109] This is more favorable as breath odors are not limited to a single or a handful of gasses describable according to their individual threshold levels. Rather, breath odors are "olfactory spectra" of breath. Every exhaled odorant gas should be

suspected as potentially contributing, by varying degrees, to the overall perception of breath odor.

In pathologic type 4 halitosis, the concentrations and profile of exhaled gases is significantly different to those seen in health, depending on the pathology. Exhaled breath volatiles are reported in diabetes mellitus, sleep apnea, *H. pylori* infection, sickle cell disease, asthma, breast cancer, lung carcinoma, chronic obstructive pulmonary disease, cystic fibrosis, liver diseases, cirrhosis, uremia, kidney failure and TMAU.^[24,94]

Breath alkanes have pungent odor are elevated in intestinal inflammation,^[110] e.g. ulcerative colitis,^[111,112] Crohn's Disease,^[112] in pulmonary tuberculosis,^[113] schizophrenia,^[114] pneumonia,^[115] asbestos-related disorders,^[116] stomach cancer,^[117] and angina pectoris.^[118] Pregnant females or pre-eclampsia patients have a specific breath gas profile, including undecane, 6-methyltridecane, 2-methylpentane, 5-methyltetradecane and 2-methylnonane.^[119] DMS, acetone, 2-butanone and 2-pentanone are reported in liver failure, including cirrhosis.^[27]

The “fedor hepaticus” of hepatic failure is largely caused by DMS, not ammonia.^[28] Elevated blood DMS (“dimethylsulfidemia”),^[28] was reported to be responsible for the majority of cases of blood borne halitosis.^[12]

Body odor may accompany Type 4 halitosis as the same volatiles are also excreted during perspiration. This is sometimes termed blood-borne body odor and halitosis. An example is TMAU, a rare condition, classically characterized by fish odor in urine, sweat, and breath.

Another potential blood-borne mechanism may contribute to a halitosis complaint when blood-borne odorants stimulate olfactory receptors via their blood supply.^[16,120] Strong olfactory receptor responses can be triggered by intravascular injection of odorants in tracheotomized animals. Such odor perceptions are not occurring by the normal air-borne route, so there may not be measurable halitosis.

Type 5 halitosis: Subjective halitosis

Subjective halitosis is a halitosis complaint without objective confirmation of halitosis by others or halitometer readings. Type 5 halitosis can be misdiagnosed if there are measurement errors or transient symptoms.

It can be considered normal for even mentally healthy individuals to worry occasionally about to be having halitosis.^[121]

Such halitosis concern can rationally dismissed by most healthy people, who have a degree of psychological resilience which is capable of compensating for stressors. This normal level of concern for halitosis constitutes the “physiologic” aspect of Type 5 halitosis.

Pathologic subjective halitosis can be categorized as psychologic or neurologic.

Psychologic causes

Psychologic factors can cause subjective halitosis. This is termed monosymptomatic hypochondriacal psychosis,^[16] a type of obsessive-compulsive spectrum disorder,^[121] or ORS. 75% of ORS patients present with halitosis complaints,^[122] but obsession over other non-existent body odors, often in combination, are included. Others' behavior (e.g. opening windows, sniffing, touching noses etc.) is misinterpreted as evidence of

halitosis. Employment loss, divorce or suicidal ideation are reported.^[123] “Doctor shopping” to find clinicians to treat the non-existent odor may occur. However, some report that TMAU or other genuine odor symptoms can be misdiagnosed as ORS.^[124]

It may be the case that the previously black and white thinking of objective halitosis on the one hand and psychologic halitosis on the other is oversimplification. Instead, it might be more accurate to consider a spectrum, with entirely subjective halitosis at one extreme and entirely objective halitosis with no psychologic concern at the other. Most patients will fall somewhere between these two points.

When objective halitosis has not been treated, it may cause the patient distress or social isolation, and eventually over-concern about halitosis may develop. Even after the odor is reduced to physiologic levels, the negative psychosocial sequelae may persist, making these cases difficult to treat. Conversely, oversensitivity to physiologic odor may be the basis of a subjective halitosis with no history of objective halitosis.

Neurogenic causes

Traditionally, subjective halitosis complaints are attributed to psychologic factors, but at least some are neurologic. Nearly 200 disorders can cause chemosensory dysfunction (CSD).^[16] Dysosmia (disordered olfaction including parosmia and phantosmia) and dysgeusia (disordered gustation) present extensive differential diagnoses.

Olfaction and gustation are intimately interlinked at the neuronal level in the brain. The definition of subjective halitosis (pseudo-halitosis) has been broadened: “the perception of an alteration in the quality of expired odor

air, a symptom perceived only by the patient.”^[16] Many patients fail to distinguish between bad taste and bad odor. Gustatory stimuli may influence orthonasal and retronasal odorant perception.^[58]

Side effects of medication, hypothyroidism, hyposalivation (another extensive differential), nutrient deficiency (zinc, copper, iron, and vitamins A and B12), trauma and tumors involving the olfactory center in the brain, or nerve damage (glossopharyngeal, vagus, chorda tympani, olfactory), neurodegenerative diseases (Parkinson's, Alzheimer's and Huntington's disease), environmental pollutants (e.g. smoking), drug abuse, certain oral hygiene products (e.g. mouthwashes) and certain foodstuffs can all be potentially involved in subjective halitosis complaints, by various mechanisms.^[16,125] As described previously, diabetes mellitus, GERD and blood-borne stimulation of taste and smell receptors via the blood circulation may also contribute to subjective halitosis.^[16,126]

NEW TERMINOLOGY

Unhelpful terms no longer needed:

- Many of the confusing array of synonyms used to describe a psychologic, subjective halitosis complaint (which would fall within type 5 halitosis) are unneeded, including pseudo-halitosis, non-genuine halitosis, delusional halitosis, olfactory obsession, psico-olfactory sensitivity, olfactory depression, halitosis anxiety and imaginary halitosis.
- Subjective, descriptive terms such as sulfurous, ammoniacal, fecal, fishy or

similar should be discontinued since they invite misunderstanding.

Useful terms that are retained:

- **Objective halitosis** refers to any combination of Types 1-4, but should not refer to type 1 (oral) halitosis exclusively.
- **Morning breath** is a temporarily increased physiologic halitosis during sleep and disappears soon after waking.^[127] Xerostomia is largely responsible,^[128] resulting from diminished salivary and respiratory secretion during sleep, especially when the mouth remains open. Proteinaceous substrates in saliva allows for microbial action, and release of VSC and other volatiles, thereby enhancing Type 1 and 2 halitosis. Increased breath ammonia, acetone,^[97,129] and isoprene,^[127] occur after overnight fasting. Intestinal gas builds up in the colon during sleep,^[130] possibly due to immobility and microbial fermentation of intestinal contents. More type 4 halitosis might result, or possibly, more gas leakage from the gastroesophageal valve (i.e. type 3). All the above mechanisms may operate during sleep. The resultant halitosis upon waking can be termed morning breath, in reality an enhanced form of Type 0 halitosis.
- **Psychosomatic halitosis** should be retained, but the term should not be misused. Some hypothesize that anxiety enhances oral VSC production.^[131] This mechanism is correctly termed psychosomatic, since

a physical symptom is being influenced by psychologic factors. This is the uniquely correct usage of the term “psychosomatic halitosis”, rather than previous meanings (see “Previous terminology”).

- **Self halitosis** has been used to describe a lack of objective halitosis even though the patient believes themselves to have halitosis,^[32] but it is better used to define endogenously produced, self perceived odor, which is not a detectable odor to others. By true description, self halitosis appears in three forms: retronasal olfaction, olfactory receptor responses triggered by blood-borne odorants, and phantom tastes/odors.
- **Halitophobia** should be retained with correct meaning. It refers to "fear of having halitosis" but not "untreated halitosis".

New terms

- **Exogenous odor** results from consumption of aromatic foodstuffs (e.g. garlic, onion, spicy foods), beverages (e.g. alcohol) or tobacco. Exogenous volatiles may be released transiently from residues of food or drink in the mouth, or released unchanged via the blood-borne mechanism after being absorbed. Such odors are distinguished from pathologic halitosis, e.g. garlic smells like garlic. The terms garlic odor, spice odor, etc. seem suitable. Dietary or temporary halitosis are also terms that could be argued to be useful.
- Halitosis is an **endogenous odor** because it is produced in the body

DISCUSSION

The new definition places less importance on organoleptic examination and single occasion halitometric reading, and instead places more emphasis on the declarations of the patient and his/her social environment. The reasoning for this follows.

Organoleptic examination

Organoleptic measurement is carried out by smelling the patient's breath then scoring the level of halitosis.^[7] However, the examiner does not smell a pure sample of mouth air, but rather a mixture of mouth air and alveolar air. The organoleptic examination does not distinguish between these, only subjectively assesses the overall odor level.

The perception of odorants depends upon several factors, including constant fluctuations in the clinician's individual threshold level for that specific odor, what was last smelled before the examination, the concentration and volatility of the molecules themselves, room temperature (gases are less volatile in lower temperatures), humidity of exhaled breath, how strongly the breath is blown into the examiner's nose (less forcefully expired breath will consist of less volume of air, and less odorant molecules will be carried to the examiner's olfactory epithelia), and lastly the examiner's concentration at that moment. All these parameters vary from one hour to the next and from one individual to the next, making this a subjective measure which does not reflect the actual level of odor. It can be suggested that self-applied organoleptic scoring (self assessment) should be evaluated to monitorize prognosis.

Organoleptic examination is problematic,^[132] and objectionable to both dentists and to patients. Dislike or shame is experienced by 50% of patients with this examination (n=283).^[133] Some use a privacy screen to prevent the patient from seeing the examiner during the examination.^[7] Examiners find it repulsive to smell a halitosis patient's breath.

Self detection of halitosis correlated positively with actual halitosis only when subjects smelt their own saliva isolated from their mouth. Other methods did not correlate.^[134] Another study reported less correlation between self detection of halitosis and clinical findings. The sensitivity and specificity of self-perceived oral malodor were 47.2% and 59.2%, respectively.^[135] The same author later compared 252 halitosis patients' self-estimation, organoleptic and halitometric results and found that self-estimated corresponded significantly with clinical oral malodor.^[136]

Halimeters

Gas chromatography (GC), alone or combined with mass spectrometry (MS), is most frequently utilized for highly sensitive VSC detection (1-10 ppb). Nevertheless, routine application of these clinically is impractical given the expense and complexity, and the expertise required.^[94] More practical methods utilize colorimetric hydrogen sulfide sensors engineered both as an optical fibre, capable of measuring reflectance change of an immobilized reagent,^[137] and as thin reactive films of chromophores.^[138] A bio-electronic nose capable of detecting the oxygen consumption induced by an enzymatic reaction with methyl sulfide has also been developed.^[139] The Halimeter,^[140] contains an

electrochemical sensor for VSC. The semiconductor gas sensors Breathron,^[141] constructed as a zinc oxide film with specificity to hydrogen sulfide and mercaptans.^[142] The GC-based OralChroma,^[143] is portable equipment capable of determining combined H₂S, MM and DMS levels, with a 10 min response time and a detection limit of a few ppb. Twin Breasor,^[144] Diamond Probe/Perio 2000,^[145] Cyranose 320,^[146] and B/B Checker,^[147] are portable devices for detecting several gases including VSC and other odorous gases in mouth or breath air.^[148,149] Their accuracy is poor compared to GC and MS. They cannot distinguish one odor from another, and they have difficulty distinguishing individual compounds from the family of VSC.^[132]

Almost all halitosis researchers and specialists use portable sulfide monitors (e.g. Halimeter) to detect oral VSC.^[14] Good correlation exists between Halimeter readings and VSC concentration,^[35] and sulfur-producing bacteria levels.^[150] However, Halimeter readings are imprecise, and misdiagnosis may result.^[151] The Halimeter has biexponential response to a constant concentration of VSC. Rapid (peak) and slow (plateau) responses differed. The total VSC in air samples was 2.7 times greater than at its peak concentration, but its plateau phase measurement is 25% greater than the actual concentration. A modified protocol measuring plateau instead of peak values is available, yielding more favorable correlation with the actual level of VSC.^[152]

In order to investigate the Halimeter's ability to distinguish between VSC and other gases, having calibrated the Halimeter to ambient air, the aspirating tube was inserted into the headspace of some 250 ml

commercial juice cartons immediately after opening. The Halimeter readings for apricot, apple, peach, cherry juices, buttermilk, soda, were 114, 352, 91, 48, 39, 47 ppb VSC respectively. In a similar experiment, the Halimeter reported VSC as if H₂S is emitted from various flowers: daffodil, rose, jasmine were 255, 42, 73 ppb while 104 ppb was read near a sump, and 417 ppb near hand soap. When using another gas detector in the same conditions, all these flowers read with different percentages of VOC, not VSC.^[153] Such simple experiments show that the Halimeter seems to confuse VSC with other odorants, and may not be selective enough for halitosis. The OralChroma gives more comprehensive VSC level readings than the Halimeter,^[41] but it shares the VSC exclusivity limitation, and therefore cannot fully determine the actual level of breath odor due to potential minor contributions from non-VSC gases.

New gas detectors capable of detecting sulfur and nitrogen containing gases, as well as VOCs should be developed for use in halitosis detection. There are industrial, portable gas detectors that are capable of detect more than 4 gas groups including VSC, NH₃, or VOC that could potentially be utilized at one reading. A sensor system for monitoring the simple gases H₂, CO, H₂S, NH₃, VOC and ethanol,^[154] and breath test kits including instruments to detect breath H₂ and methane are available.^[155]

Perturbation on threshold of halitosis

There is no consensus regarding what VSC reading corresponds to clinically present halitosis (see Table 3).

VSC thresholds should be revisited to improve clinical utility.^[163] According to the

new concepts described in this paper, there is no need to establish any precise VSC level which constitutes a halitosis diagnosis. Any patient complaining of halitosis is at least Type 5, even if objective halitosis is not diagnosed. Treatment should be targeted reducing pathologic halitosis to physiologic halitosis. Setting the goal at zero odor is unrealistic and arguably impossible.

Table 3. Variation in the “halitosis threshold” reported in the literature	
Halitosis threshold (VSC ppb)	Reference
75	[156]
100 (2*)	[7,31,157,158]
110	[12]
125	[40]
150	[14,35,94,159]
250 (3*)	[81,160,161]
Total: VSC 250	[81]
H ₂ S, CH ₃ SH, (CH ₃) ₂ S: 150, 50, 20 respectively (3*)	
<i>Besides these data, some describe ranges of VSC readings, e.g.: 0-40, healthy; 41-60, physiologic; 61-80, slight; 81-110, moderate; 111-140, severe; over 141, very strong.[162]</i>	
<i>* organoleptic score</i>	

There are three reasons to restrict the use of halitometers. Firstly, since baseline mouth air VSC concentrations fluctuate throughout day,^[151] halitometric reading at any particular time may not be representative. For this reason, multiple halitometric examinations carried out at different times throughout the day may be more representative compared to a single occasion in the dental clinic. Or cysteine challenge,^[164] should be applied to decide optimal VSC level of that individual.

Secondly, popular, portable halitometers are simply sulfide detectors, capable of detecting only VSC. However,

nonsulfurous gases are also present in the mouth or breath, albeit in a lesser concentration than VSC. Halitometers are poor at distinguishing one odor from another. E.g., in TMAU, the breath could be malodorous due to the presence of TMA, and VSC levels may be under the normal range in such patients. Thus, examiners may misdiagnose some objective halitosis cases as if subjective halitosis by relying entirely on the specificity of halitometers.

Thirdly, there is no scientifically accepted quantitative threshold between physiologic odor and pathologic halitosis.

References

- Quirynen M, Van den Velde S, Vandekerckhove B, and Dadamio J in Newman MG, Takei HH, Klokkevold PR, Carranza FA (editors) Carranza's clinical periodontology 11th edition 2012 Elsevier/Saunders, St. Louis, Mo. pp. 331-338
- Winkel EG in Lindhe J, Lang NP, Karring T (editors) Clinical periodontology and implant dentistry 5th edition 2008 Blackwell Munksgaard Oxford pp.1325-1337
- Cortelli JR, Barbosa MD, Westphal MA. Halitosis: a review of associated factors and therapeutic approach. Braz Oral Res. 2008;22 Suppl 1:44-54.
- Outhouse TL, Al-Alawi R, Fedorowicz Z, Keenan JV. Tongue scraping for treating halitosis. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005519.
- Fedorowicz Z, Aljufairi H, Nasser M, Outhouse TL, Pedrazzi V. Mouthrinses for the treatment of halitosis. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006701.
- Miyazaki H, Arao M, Okamura K, Kawaguchi Y, Toyofuku A, Hoshi K, Yaegaki K. "[Tentative classification of halitosis and its treatment needs] (Japanese)". Niigata Dental Journal 1999;32: 7-11.
- Yaegaki K, Coil JM. Examination, classification, and treatment of halitosis; clinical perspectives. J Can Dent Assoc. 2000 May;66(5):257-61.
- Murata T, Yamaga T, Iida T, Miyazaki H, Yaegaki K. Classification and examination of halitosis. Int Dent J. 2002 Jun;52 Suppl 3:181-6.
- Yaegaki K, Coil JM. Genuine halitosis, pseudo-halitosis, and halitophobia: classification, diagnosis, and treatment. Compend Contin Educ Dent. 2000 Oct;21(10A):880-6, 888-9; quiz 890.
- Tangerman A, Winkel EG. Extra-oral halitosis: an overview. J Breath Res. 2010 Mar;4(1):017003.
- Tangerman A. Halitosis in medicine: a review. Int Dent J. 2002 Jun;52 Suppl 3:201-6.
- Tangerman A, Winkel EG. Intra- and extra-oral halitosis: finding of a new form of extra-oral blood-borne halitosis caused by dimethyl sulphide. J Clin Periodontol. 2007 Sep;34(9):748-55.

13. Motta LJ, Bachiega JC, Guedes CC, Laranja LT, Bussadori SK. Association between halitosis and mouth breathing in children. *Clinics (Sao Paulo)*. 2011;66(6):939-42.
14. Richter JL. Diagnosis and treatment of halitosis. *Compend Contin Educ Dent*. 1996 Apr;17(4):370-2, 374-6 passim; quiz 388.
15. Iwu CO, Akpata O. Delusional halitosis. Review of the literature and analysis of 32 cases. *Br Dent J*. 1990 Apr 7;168(7):294-6.
16. Falcão DP, Vieira CN, Batista de Amorim RF. Breaking paradigms: a new definition for halitosis in the context of pseudo-halitosis and halitophobia. *J Breath Res*. 2012 Mar;6(1):017105.
17. Seemann R, Bizhang M, Djamchidi C, Kage A, Nachnani S. The proportion of pseudo-halitosis patients in a multidisciplinary breath malodour consultation. *Int Dent J*. 2006 Apr;56(2):77-81.
18. Videbech T. Chronic olfactory paranoid syndromes. A contribution to the psychopathology of the sense of smell. *Acta Psychiatr Scand*. 1966;42(2):183-213.
19. Takahashi T. A social club spontaneously formed by ex-patients who had suffered from anthropophobia (Taijin kyofu (sho)). *Int J Soc Psychiatry*. 1975 Summer;21(2):137-40.
20. Rosenberg M, Leib E. Introduction. In Rosenberg M (editor). *Bad breath: research perspectives*, 2nd edition. Ramot Publishing - Tel Aviv University; 1997 pp. 9-13.
21. Lochner C, Stein DJ. Olfactory reference syndrome: diagnostic criteria and differential diagnosis. *J Postgrad Med*. 2003 Oct-Dec;49(4):328-31.
22. Phillips KA. How to help patients with olfactory reference syndrome. Delusion of body odor causes shame, social isolation. *The Journal of Family Practice*, 2007; 6(3):1
23. Zaitu T, Ueno M, Shinada K, Wright FA, Kawaguchi Y. Social anxiety disorder in genuine halitosis patients. *Health Qual Life Outcomes*. 2011 Nov 3;9:94.
24. Whittle CL, Fakharzadeh S, Eades J, Preti G. Human breath odors and their use in diagnosis. *Ann N Y Acad Sci*. 2007 Mar;1098:252-66.
25. Smith D, Turner C, Spaněl P. Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. *J Breath Res*. 2007 Sep;1(1):014004.
26. Enderby B, Lenney W, Brady M, Emmett C, Spaněl P, Smith D. Concentrations of some metabolites in the breath of healthy children aged 7-18 years measured using selected ion flow tube mass spectrometry (SIFT-MS). *J Breath Res*. 2009 Sep;3(3):036001.
27. Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. GC-MS analysis of breath odor compounds in liver patients. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2008 Nov 15;875(2):344-8.
28. Harvey-Woodworth CN. Dimethylsulphidemia: the significance of dimethyl sulphide in extra-oral, blood borne halitosis. *Br Dent J*. 2013 Apr 12;214(7):E20.
29. Coulthwaite L, Verran J. Development of an in vitro denture plaque biofilm to model denture malodour. *J Breath Res*. 2008 Mar;2(1):017004.
30. Davies S, Spanel P, Smith D. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. *Kidney Int*. 1997 Jul;52(1):223-8.
31. Bollen CM, Beikler T. Halitosis: the multidisciplinary approach. *Int J Oral Sci*. 2012 Jun;4(2):55-63.
32. Yaegaki K, Coil JM. Clinical dilemmas posed by patients with psychosomatic halitosis. *Quintessence Int*. 1999; 18:328-33.
33. Aydin M. [Halitosis. In: Oral Microbiology]. Aydin M, Mısırlıgil A (eds). 2012 Ankara: MN Medical & Nobel, p.97-104. Turkish.
34. Phillips M, Cataneo RN, Greenberg J, Munawar M, Nachnani S, Samtani S. Pilot study of a breath test for volatile organic compounds associated with oral malodor: evidence for the role of oxidative stress. *Oral Dis*. 2005;11 Suppl 1:32-4.
35. Van den Velde S, van Steenberghe D, Van Hee P, Quirynen M. Detection of odorous compounds in breath. *J Dent Res*. 2009 Mar;88(3):285-9.
36. Dadamio J, Van Tornout M, Van den Velde S, Federico R, Dekeyser C, Quirynen M. A novel and visual test for oral malodour: first observations. *J Breath Res*. 2011 Dec;5(4):046003.
37. Hartley M G, El-Maaytah M A, McKenzie C and Greenman J 1996 The tongue microbiota of low odour and malodorous individuals *Micro. Ecol. Health Dis*. 9 215–23
38. Hess J, Greenman J, Duffield J. Modelling oral malodour from a tongue biofilm. *J Breath Res*. 2008 Mar;2(1):017003.
39. Aydin M. [Anaerobic bacteria and Anaerobism, Microbial biofilms and aerosols In:Microbiology in Dentistry and Medicine]. Cengiz T, Mısırlıgil A, Aydin M (editors). 2004 Ankara: Güneş Medical, pp. 175-180, 569-576. Turkish
40. Kozeowski Z, Mikeaszewska BB, Konopka T, Kawa ZD, Lewczyk E. (2007). Using a Halitometer to Verify the Symptoms of Halitosis. *Adv Clin Exp Med*.16(3): 411-416.
41. Salako NO, Philip L. Comparison of the use of the Halimeter and the Oral Chroma™ in the assessment of the ability of common cultivable oral anaerobic bacteria to produce malodorous volatile sulfur compounds from cysteine and methionine. *Med Princ Pract*. 2011;20(1):75-9.
42. Aydin M. [Odorigenic bacteria In Halitosis]. 2008 Istanbul, Nobel medical, pp: 65-82. Turkish
43. Zürcher A, Filippi A. Findings, diagnoses and results of a halitosis clinic over a seven year period. *Schweiz Monatsschr Zahnmed*. 2012;122(3):205-16. English, German.
44. Delanghe G, Bollen C, Desloovere C. [Halitosis--foetor ex ore]. *Laryngorhinootologie*. 1999 Sep;78(9):521-4. German.
45. Quirynen M, Dadamio J, Van den Velde S, De Smit M, Dekeyser C, Van Tornout M, Vandekerckhove B. Characteristics of 2000 patients who visited a halitosis clinic. *J Clin Periodontol*. 2009 Nov;36(11):970-5.
46. Bollen CM, Rompen EH, Demanez JP. [Halitosis: a multidisciplinary problem]. *Rev Med Liege*. 1999 Jan;54(1):32-6. Review. French.
47. Fletcher SM, Blair PA. Chronic halitosis from tonsilloliths: a common etiology. *J La State Med Soc*. 1988 Jun;140(6):7-9.
48. Lanza DC. Diagnosis of chronic rhinosinusitis. *Ann Otol Rhinol Laryngol Suppl*. 2004 May;193:10-4.
49. Bunzen DL, Campos A, Leão FS, Morais A, Sperandio F, Caldas Neto S. Efficacy of functional endoscopic sinus surgery for symptoms in chronic rhinosinusitis with or without polyposis. *Braz J Otorhinolaryngol*. 2006 Mar-Apr;72(2):242-6.
50. Tatli MM, San I, Karaoglanoglu M. Paranasal sinus computed tomographic findings of children with chronic cough. *Int J Pediatr Otorhinolaryngol*. 2001 Sep 28;60(3):213-7.
51. Schlosser RJ, Harvey RJ. (2008). *Diagnosis of Chronic Rhinosinusitis*. In: Rhinosinusitis. Thaler ER, Kennedy DW, editors. New York: Springer LLC, p.43.
52. Yücel A, Dereköy FS, Yılmaz MD, Altuntaş A. [Effects of Sinonasal Anatomical Variations on Paranasal Sinus Infections]. *The Medical Journal of Kocatepe*, 2004;5: 43-47.
53. Amir E, Shimonov R, Rosenberg M. Halitosis in children. *J Pediatr*. 1999 Mar;134(3):338-43.

54. Morice AH. Post-nasal drip syndrome--a symptom to be sniffed at? *Pulm Pharmacol Ther.* 2004;17(6):343-5.
55. Ng DK, Chow PY, Kwok KL. Halitosis and the nose. *Hong Kong Med J.* 2005 Feb;11(1):71-2.
56. Stoodley P, Debeer D, Longwell M, Nistico L, Hall-Stoodley L, Wenig B, Krespi YP. Tonsillolith: not just a stone but a living biofilm. *Otolaryngol Head Neck Surg.* 2009 Sep;141(3):316-21.
57. Tsuneishi M, Yamamoto T, Kokeguchi S, Tamaki N, Fukui K, Watanabe T. Composition of the bacterial flora in tonsilloliths. *Microbes Infect.* 2006 Aug;8(9-10):2384-9.
58. Welge-Lüssen A, Husner A, Wolfensberger M, Hummel T. Influence of simultaneous gustatory stimuli on orthonasal and retronasal olfaction. *Neurosci Lett.* 2009 Apr 24;454(2):124-8.
59. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. *Otolaryngol Head Neck Surg.* 2002;127:32-5.
60. Brent, A (2010). "Chapter 46, Odor - unusual" in Fleisher GR, Ludwig S (editors) *Textbook of Pediatric Emergency Medicine* 6th edition 2010 Lippincott Williams & Wilkins pp. 402-405
61. Sethi S, Nanda R, Chakraborty T. Clinical application of volatile organic compound analysis for detecting infectious diseases. *Clin Microbiol Rev.* 2013 Jul;26(3):462-75.
62. Shirasu, M; Touhara, K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. *Journal of biochemistry* 2011 Sep;150(3):257-66.
63. Brehmer D, Riemann R. The rhinolith-a possible differential diagnosis of a unilateral nasal obstruction. *Case Rep Med.* 2010;2010:845671.
64. deShazo RD, Stringer SP. Atrophic rhinosinusitis: progress toward explanation of an unsolved medical mystery. *Curr Opin Allergy Clin Immunol.* 2011 Feb;11(1):1-7.
65. Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. *Cochrane Database Syst Rev.* 2012 Feb 15;2:CD008280.
66. Hirano I, Kahrilas PJ, Pandolfino JE, Richter JE, Soll AH, Graham DY. In Yamada T, Alpers DH, et al. (editors) *Textbook of gastroenterology* 5th edition 2009 Blackwell Pub. Chichester, West Sussex pp. 732,742,772,951
67. Wyman JB, Dent J, Heddl R, Dodds WJ, Toouli J, Downton J. Control of belching by the lower oesophageal sphincter. *Gut.* 1990 Jun;31(6):639-46.
68. Di Fede O, Di Liberto C, Occhipinti G, Vigneri S, Lo Russo L, Fedele S, Lo Muzio L, Campisi G. Oral manifestations in patients with gastro-oesophageal reflux disease: a single-center case-control study. *J Oral Pathol Med.* 2008 Jul;37(6):336-40.
69. Struch F, Schwahn C, Wallaschofski H, Grabe HJ, Völzke H, Lerch MM, Meisel P, Kocher T. Self-reported halitosis and gastroesophageal reflux disease in the general population. *J Gen Intern Med.* 2008 Mar;23(3):260-6.
70. Moshkowitz M, Horowitz N, Leshno M, Halpern Z. Halitosis and gastroesophageal reflux disease: a possible association. *Oral Dis.* 2007 Nov;13(6):581-5.
71. Saberi-Firooz M, Khademolhosseini F, Yousefi M, Mehrabani D, Zare N, Heydari ST. Risk factors of gastroesophageal reflux disease in Shiraz, southern Iran. *World J Gastroenterol.* 2007 Nov 7;13(41):5486-91.
72. Kinberg S, Stein M, Zion N, Shaoul R. The gastrointestinal aspects of halitosis. *Can J Gastroenterol.* 2010 Sep;24(9):552-6.
73. Marsicano JA, de Moura-Grec PG, Bonato RC, Sales-Peres Mde C, Sales-Peres A, Sales-Peres SH. Gastroesophageal reflux, dental erosion, and halitosis in epidemiological surveys: a systematic review. *Eur J Gastroenterol Hepatol.* 2013 Feb;25(2):135-41.
74. Yoo SH, Jung HS, Sohn WS, Kim BH, Ku BH, Kim YS, Park SW, Hahm KB. Volatile sulfur compounds as a predictor for esophagogastrroduodenal mucosal injury. *Gut Liver.* 2008 Sep;2(2):113-8.
75. Kim JG, Kim YJ, Yoo SH, Lee SJ, Chung JW, Kim MH, Park DK, Hahm KB. Halimeter ppb Levels as the Predictor of Erosive Gastroesophageal Reflux Disease. *Gut Liver.* 2010 Sep;4(3):320-5.
76. Kisligh K, Wilder-Smith CH, Bornstein MM, Lussi A, Seemann R. Halitosis and tongue coating in patients with erosive gastroesophageal reflux disease versus nonerosive gastroesophageal reflux disease. *Clin Oral Investig.* 2013 Jan;17(1):159-65.
77. Tas A, Köklü S, Yüksel I, Başar O, Akbal E, Cimpek A. No significant association between halitosis and upper gastrointestinal endoscopic findings: a prospective study. *Chin Med J (Engl).* 2011 Nov;124(22):3707-10.
78. Carr MM, Nguyen A, Nagy M, Poje C, Pizzuto M, Brodsky L. Clinical presentation as a guide to the identification of GERD in children. *Int J Pediatr Otorhinolaryngol.* 2000 Aug 11;54(1):27-32.
79. Lee H, Kho HS, Chung JW, Chung SC, Kim YK. Volatile sulfur compounds produced by *Helicobacter pylori*. *J Clin Gastroenterol.* 2006 May-Jun;40(5):421-6.
80. Lechner M, Karlseder A, Niederseer D, Lirk P, Neher A, Rieder J, Tilg H. *H. pylori* infection increases levels of exhaled nitrate. *Helicobacter.* 2005 Oct;10(5):385-90.
81. Suzuki N, Yoneda M, Naito T, Iwamoto T, Masuo Y, Yamada K, Hisama K, Okada I, Hirofujii T. Detection of *Helicobacter pylori* DNA in the saliva of patients complaining of halitosis. *J Med Microbiol.* 2008 Dec;57(Pt 12):1553-9.
82. Katsinelos P, Tziomalos K, Chatzimavroudis G, Vasiliadis T, Katsinelos T, Pilpilidis I, Triantafyllidis I, Paroutoglou G, Papaziogas B. Eradication therapy in *Helicobacter pylori*-positive patients with halitosis: long-term outcome. *Med Princ Pract.* 2007;16(2):119-23.
83. Serin E, Gumurdulu Y, Kayaselcuk F, Ozer B, Yilmaz U, Boyacioglu S. Halitosis in patients with *Helicobacter pylori*-positive non-ulcer dyspepsia: an indication for eradication therapy? *Eur J Intern Med.* 2003 Feb;14(1):45-48.
84. Shashidhar H, Peters J, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for pediatric *Helicobacter pylori* infection. *J Pediatr Gastroenterol Nutr.* 2000 Mar;30(3):276-82.
85. Gasbarrini A, Ojetti V, Pitocco D, Franceschi F, Candelli M, Torre ES, Gabrielli M, Cammarota G, Armuzzi A, Pola R, Pola P, Ghirlanda G, Gasbarrini G. Insulin-dependent diabetes mellitus affects eradication rate of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol.* 1999 Jul;11(7):713-6.
86. Ierardi E, Amoroso A, La Notte T, Francavilla R, Castellana S, Marrazza E, Monno RA, Francavilla A. Halitosis and *Helicobacter pylori*: a possible relationship. *Dig Dis Sci.* 1998 Dec;43(12):2733-7.
87. Tiomny E, Arber N, Moshkowitz M, Peled Y, Gilat T. Halitosis and *Helicobacter pylori*. A possible link? *J Clin Gastroenterol.* 1992 Oct;15(3):236-7.
88. Chen X, Tao DY, Li Q, Feng XP. [The relationship of halitosis and *Helicobacter pylori*]. *Shanghai Kou Qiang Yi Xue.* 2007 Jun;16(3):236-8. Chinese.
89. Adler I, Denninghoff VC, Alvarez MI, Avagnina A, Yoshida R, Elsner B. *Helicobacter pylori* associated with glossitis and halitosis. *Helicobacter.* 2005 Aug;10(4):312-7.

90. Li XB, Liu WZ, Ge ZZ, Zhang DR, Zhao YJ, Dai J, Xue HB, Xiao SD. Analysis of clinical characteristics of dyspeptic symptoms in Shanghai patients. *Chin J Dig Dis.* 2005;6(2):62-7.
91. Tangerman A, Winkel EG, de Laat L, van Oijen AH, de Boer WA. Halitosis and *Helicobacter pylori* infection. *J Breath Res.* 2012 Mar;6(1):017102.
92. Dore MP, Fanciulli G, Tomasi PA, Realdi G, Delitala G, Graham DY, Malaty HM. Gastrointestinal symptoms and *Helicobacter pylori* infection in school-age children residing in Porto Torres, Sardinia, Italy. *Helicobacter.* 2012 Oct;17(5):369-73.
93. Imanzadeh F, Imanzadeh A, Sayyari AA, Yagenah M, Javaherizadeh H, Hatamian B. *Helicobacter pylori* infection; in cases with and without subjective halitosis. *Professional Med J.* 2010; 17(4): 543-545.
94. Ciaffoni L, Peverall R, Ritchie GA. Laser spectroscopy on volatile sulfur compounds: possibilities for breath analysis. *J Breath Res.* 2011 Jun;5(2):024002.
95. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. Variation in volatile organic compounds in the breath of normal humans. *J Chromatogr B Biomed Sci Appl.* 1999 Jun 11;729(1-2):75-88.
96. Diskin AM, Spanel P, Smith D. Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. *Physiol Meas.* 2003 Feb;24(1):107-19.
97. Schmidt FM, Vaittinen O, Metsälä M, Lehto M, Forsblom C, Groop PH, Halonen L. Ammonia in breath and emitted from skin. *J Breath Res.* 2013 Mar;7(1):017109.
98. Wang T, Pysanenko A, Dryahina K, Spanel P, Smith D. Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. *J Breath Res.* 2008 Sep;2(3):037013.
99. Turner C, Spanel P, Smith D. A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. *Physiol Meas.* 2006 Jul;27(7):637-48.
100. Turner C, Parekh B, Walton C, Spanel P, Smith D, Evans M. An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. *Rapid Commun Mass Spectrom.* 2008;22(4):526-32.
101. Turner C, Spanel P, Smith D. A longitudinal study of ethanol and acetaldehyde in the exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry. *Rapid Commun Mass Spectrom.* 2006;20(1):61-8.
102. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. *Biomarkers.* 2002 Jan-Feb;7(1):1-32.
103. Phillips M, Greenberg J, Cataneo RN. Effect of age on the profile of alkanes in normal human breath. *Free Radic Res.* 2000 Jul;33(1):57-63.
104. Blom HJ, Tangerman A. Methanethiol metabolism in whole blood. *J Lab Clin Med.* 1988 Jun;111(6):606-10.
105. Hamilton LH. *Breath tests & Gastroenterology.* Second edition, 1998 Quintron Co, WI p.10
106. Probert CS, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. *J Gastrointest Liver Dis.* 2009 Sep;18(3):337-43.
107. Phillips M. Breath tests in medicine. *Sci Am.* 1992 Jul;267(1):74-9.
108. Leonardos G, Kendall D, Barnard N. Odor Threshold Determinations of 53 Odorant Chemicals *Journal of the Air Pollution Control Association* Vol. 19, Iss. 2, 1969
109. Bofan M, Mores N, Baron M, Dabrowska M, Valente S, Schmid M, Trovè A, Conforto S, Zini G, Cattani P, Fuso L, Mautone A, Mondino C, Pagliari G, D'Alessio T, Montuschi P. Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. *J Breath Res.* 2013 Mar;7(1):017103.
110. Kokoszka J, Nelson RL, Swedler WI, Skosey J, Abcarian H. Determination of inflammatory bowel disease activity by breath pentane analysis. *Dis Colon Rectum.* 1993; 36(6):597-601.
111. Sedghi S, Keshavarzian A, Klamut M, Eiznhamer D, Zarling EJ. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. *Am J Gastroenterol.* 1994;89(12):2217-2221.
112. Pelli MA, Trovarelli G, Capodicasa E, De Medio GE, Bassotti G. Breath alkanes determination in ulcerative colitis and Crohn's disease. *Dis Colon Rectum.* 1999; 42(1):71-76.
113. Phillips M, Dalay VB, Bothamley G, Cataneo RN, Lam PK, Natividad MPR, Schmitt P, Wai J. Breath biomarkers of active pulmonary tuberculosis. *Tuberculosis.* 2010; 90(2):145-151.
114. Phillips M, Erickson GA, Sabas M, Smith JP, Greenberg J. Volatile organic compounds in breath of patients with schizophrenia. *J Clin Pathol.* 1995; 48:466-469.
115. Julak J, Stranska E, Rosova U, Geppert H, Spanel P, Smith D. Bronchoalveolar lavage examined by solid phase microextraction, gas chromatography-mass spectrometry and selected ion flow tube mass spectrometry. *Journal of Microbiological Methods.* 2006; 65:76-86
116. Chapman EA, Thomas PS, Yates DH. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. *J Breath Res.* 2010 Sep;4(3):034001.
117. Ligor T, Szeliga J, Jackowski M, Buszewski B. Preliminary study of volatile organic compounds from breath and stomach tissue by means of solid phase microextraction and gas chromatography-mass spectrometry. *J Breath Res.* 2007 Sep;1(1):016001.
118. Phillips M, Cataneo RN, Greenberg J, Grodman R, Salazar M. Breath Markers of Oxidative Stress in Patients with Instable Angina. *Hearth Diseases.* 2003;5(2):85-99.
119. Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. *American Journal of Obstetrics and Gynecology.* 2004, 190:1184-1190.
120. Maruniak JA, Silver WL, Moulton DG. Olfactory receptors respond to blood-borne odorants. *Brain Res.* 1983 Apr 18;265(2):312-6.
121. Stein DJ, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome an obsessive-compulsive spectrum disorder?: two cases and a discussion. *J Neuropsychiatry Clin Neurosci.* 1998 Winter;10(1):96-9.
122. Phillips KA, Menard W. Olfactory reference syndrome: demographic and clinical features of imagined body odor. *Gen Hosp Psychiatry.* 2011 Jul-Aug;33(4):398-406.
123. Cruzado L, Cáceres-Taco E, Calizaya JR. Apropos of an Olfactory Reference Syndrome case. *Actas Esp Psiquiatr.* 2012 Jul-Aug;40(4):234-8.
124. Wise PM, Eades J, Tjoa S, Fennessey PV, Preti G. Individuals reporting idiopathic malodor production: demographics and incidence of trimethylaminuria. *Am J Med.* 2011 Nov;124(11):1058-63.
125. Bromley SM. Smell and taste disorders: a primary care approach. *Am Fam Physician.* 2000 Jan 15;61(2):427-36, 438.
126. Pacheco-Galván A, Hart SP, Morice AH. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. *Arch Bronconeumol.* 2011 Apr;47(4):195-203.

127. Cailleux A, Allain P. Isoprene and sleep *Life Sci.*, 1989 ; 44: 1877-1880.
128. Nachnani S. The effects of Oral Rinse on halitosis. *JCDA*, 1997; 25(2):145-150
129. Schwarz K, Pizzini A, Arendacká B, Zerlauth K, Filipiak W, Schmid A, Dzien A, Neuner S, Lechleitner M, Scholl-Bürgi S, Miekisch W, Schubert J, Unterkofler K, Witkovský V, Gastl G, Amann A. Breath acetone-aspects of normal physiology related to age and gender as determined in a PTR-MS study. *J Breath Res.* 2009 Jun;3(2):027003
130. Tangerman A. Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2009 Oct 15;877(28):3366-77.
131. Calil CM, Klein F. (2006). Influence of anxiety on the production of oral volatile sulfur compounds. *Life Sciences* 79(7): 660-664.
132. Oral malodor. ADA council on scientific affairs. *J Am Dent Assoc* 2003;134(2): 209-214 doi: 10.14219/jada.archive.2003.0135
133. Aydin M. Gas measurement protocols in halitosis patients. (Unpublished data)
134. Rosenberg M, Kozlovsky A, Gelernter I, Cherniak O, Gabbay J, Baht R, Eli I. Self-estimation of oral malodor. *J Dent Res.* 1995 Sep;74(9):1577-82.
135. Pham TA, Ueno M, Shinada K, Kawaguchi Y. Comparison between self-perceived and clinical oral malodor. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2012 Jan;113(1):70-80.
136. Pham TA. Comparison between self-estimated and clinical oral malodor. *Acta Odontol Scand.* 2013 Jan;71(1):263-70.
137. Fernández JR, Pereiro R, Medel AS. Optical fibre sensor for hydrogen sulphide monitoring in mouth air. *Analytica Chimica Acta.* Volume 471, Issue 1, 23 October 2002, Pages 13–23
138. Wallace KJ, Cordero SR, Tan CP, Lynch VM, Anslyn EV. A colorimetric response to hydrogen sulfide. Volume 120, Issue 2, 10 January 2007, Pages 362–367.
139. Mitsubayashia K, Minamide T, Otsuka K, Kudo H, Saito A. Optical bio-sniffer for methyl mercaptan in halitosis. *Analytica Chimica Acta*, 2006; 573-574: 75-80
140. "Halimeter" Interscan Corporation, Chatsworth, CA, USA
141. "Breathtron" New Cosmos Electric Co., Ltd, Osaka, Japan
142. Tanda N, Washio J, Ikawa K, Suzuki K, Koseki T, Iwakura M. A new portable sulfide monitor with a zinc-oxide semiconductor sensor for daily use and field study. *Journal of Dentistry* , 2007; 35(7):552-557
143. "OralChroma" Abimedical Corporation, Osaka, Japan
144. Yaegaki K, Brunette DM, Tangerman A, Choe YS, Winkel EG, Ito S, Kitano T, Ii H, Calenic B, IshkitievN, Ima T. Standardization of clinical protocols in oral malodor research. 2012 *J. Breath Res.* 6 017101. doi:10.1088/1752-7155/6/1/017101
145. "Diamond Probe/Perio 2000" Diamond General Development Corp., MI, USA
146. "Cyrano 320" Intopsys, Pasadena, CA, USA
147. Tamaki N, Kasuyama K, Esaki M, Toshikawa T, Honda SI, Ekuni D, Tomofuji T, Morita M. A new portable monitor for measuring odorous compounds in oral, exhaled and nasal air. *BMC Oral Health*, 2011; 11:15.
148. Cheng ZJ, Warwick G, Yates DH, Thomas PS. An electronic nose in the discrimination of breath from smokers and non-smokers: a model for toxin exposure. *J Breath Res.* 2009 Sep;3(3):036003.
149. Tamaki N, Kasuyama K, Esaki M, Toshikawa T, Honda S, Ekuni D, Tomofuji T, Morita M. A new portable monitor for measuring odorous compounds in oral, exhaled and nasal air. *BMC Oral Health.* 2011 Apr 20;11:15.
150. Pratten J, Pasu M, Jackson G, Flanagan A, Wilson M. Modelling oral malodour in a longitudinal study. *Archives of Oral Biology.* 2003; 48: 737-743.
151. Yaegaki K, Brunette DM, Tangerman A, Choe YS, Winkel EG, Ito S, Kitano T, Ii H, Calenic B, Ishkitiev N, Imai T. Standardization of clinical protocols in oral malodor research. *J Breath Res.* 2012 Mar;6(1):017101.
152. Furne J, Majerus G, Lenton P, Springfield J, Levitt DG, Levitt MD (2002). Comparison of volatile sulfur compound concentrations measured with a sulfide detector vs. gas chromatography. *J Dent Res* 81:140-143.
153. Aydın M. Treatment of halitosis. presented at: 6th international congress of the Istanbul University Dentistry Faculty 2013 Nov 21-23, Istanbul, Türkiye
154. Costello BPJL, Ewen RJ, Ratcliffe NM. A sensor system for monitoring the simple gases hydrogen, carbon monoxide, hydrogen sulfide, ammonia and ethanol in exhaled breath. *J. Breath Res*, 2008; 2:037011.
155. (e.g.) "BreathTracker", QuinTron, USA).
156. Rösing CK, Loesche W. Halitosis: an overview of epidemiology, etiology and clinical management. *Braz Oral Res.* 2011 Sep-Oct;25(5):466-71
157. Lin MI, Flaitz CM, Moretti AJ, Seybold SV, Chen JW. Evaluation of halitosis in children and mothers. *Pediatr Dent.* 2003 Nov-Dec;25(6):553-8.
158. Suzuki N, Yoneda M, Naito T, Iwamoto T, Hirofuji T. Relationship between halitosis and psychologic status. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008;106:542-7
159. Halimeter user manual
160. Suzuki N, Yoneda M, Naito T, Inamitsu T, Yamada K, Okada I, Hatano Y, Iwamoto T, Masuo Y, Fujimoto A and Hirofuji T. Association between oral malodour and psychological characteristics in subjects with neurotic tendencies complaining of halitosis. *International Dental Journal* 2011; 61: 57–62
161. Tanaka M, Anguri H, Nishida N, Ojima M, Nagata H, Shizukuishi S. (2003). Reliability of clinical parameters for predicting the outcome of oral malodor treatment. *J Dent Res* 82: 518-522.
162. Nachnani, S. Efficacy of Zinc Chloride Based Mouth Rinse (BreathRx™) compared to chlorine Dioxide Based Mouth Rinse (Oxyfresh™)., Clinical Data; 2000
163. Vandekerckhove B, Van den Velde S, De Smit M, Dadamio J, Teughels W, Van Tornout M, Quirynen M. Clinical reliability of non-organoleptic oral malodour measurements. *J Clin Periodontol.* 2009 Nov;36(11):964-9.
164. Kleinberg I, Codipilly DM. Cystein challenge testing: a powerful tool for examining oral malodour processes and treatments in vivo. *International Dental Journal.* 2002; 52:221-228.